B_HHS OPA FPAR 2.0 Data Elements 12.15.21.xlsx
Family Planning Annual Report 2.0
B_HHS OPA FPAR 2.0 Data Elements 12.15.21.xlsx
OMB: 0990-0479
Document [xlsx]
Download: xlsx | pdf
READ ME
FPAR 2.0 Data Elements
Pap Smear Tests Panel (86662-4)
HPV Tests Panel (86658-2)
Chlamydia Tests Panel (86659-0)
Neis. Gonorrhea Panel (86660-8)
CT+NG Com Tests Panel (86661-6)
HIV 1 & 2 Tests Panel (86657-4)
Syphilis Tests Panel
Overview
Version LogREAD ME
FPAR 2.0 Data Elements
Pap Smear Tests Panel (86662-4)
HPV Tests Panel (86658-2)
Chlamydia Tests Panel (86659-0)
Neis. Gonorrhea Panel (86660-8)
CT+NG Com Tests Panel (86661-6)
HIV 1 & 2 Tests Panel (86657-4)
Syphilis Tests Panel
Sheet 1: Version Log
Department of Health & Human Services and Office of Population Affairs logo.
|
|
| OFFICE OF POPULATION AFFAIRS FPAR 2.0 Data Elements |
|
| These are the final FPAR 2.0 data elements and associated lab panels. Additional tools are being developed to provide further implementation guidance. Please direct questions to your project officer. | |
| Version: 12/15/2021 | |
| - Update to #4 'Patient Identifier': Removed text indicating that implementation guidance is being developed to maximize client confidentiality. The 'FPAR 2.0 Implementation Guide - PDF' was posted to the OPA website on 10/8 | |
| https://opa.hhs.gov/sites/default/files/2021-10/fpar-2.0-implementation-guide-oct-2021.pdf | |
- Added #8: Added data element 'Gender Identity' to align with United States Core Data for Interoperability (USCDI) standards |
|
- Added #9: Added data element 'Sexual Orientation' to align with United States Core Data for Interoperability (USCDI) standards |
|
- Renumbered data elements based on addition of #8 and #9 |
|
| - Update to #43 'Do you want to talk about contraception or pregnancy prevention during your visit today': | |
| Removed 'Term Description' in Column C due to lack of alignment with newly available LOINC code 98076-3 | |
| Corrected 'Response Descriptions' in Column G to align with LOINC code 98076-3 | |
| Corrected 'Expected Codes/Values' in Column H to reflect correct LOINC code LL5991-6 | |
| Updated 'Notes' in Column J to include an explanation of the data element, as well as to remove text indicating that the LOINC code is pending | |
| Version: 10/1/2021 | |
- Addition of 'READ ME' tab containing instructions for how to utilize the data contained within this Excel spreadsheet |
|
| - Removed data element 'Pap test performed in last 5 years' | |
| - Changed column F from 'Answer List Name/Description' to 'Value Set/Answer List Name' | |
| - Changed column G from 'Answer List/Result Values' to 'Response Descriptions' | |
| - Changed column H from 'Answer List/Result Values Code (if available)' to 'Expected Codes/Values' | |
| - Removed column 'Binding to Answer List/Result Values'. We anticipate grantees submitting codes for all data elements, except data elements with discrete values (ex. weight) | |
| - Added Column I: 'Value Set OID (If Applicable)' to include the OID (object identifier), where available, for select value sets | |
| - Update to #41: Added newly available LOINC code to Column C (98076-3) and updated data element name in Column B to match LCN 'Do you want to talk about contraception or pregnancy prevention during your visit today' | |
| - Added 'Answer Lists/Results Values' and 'Answer Lists/Results Values Codes' to the codes in the Pap Smear Tests Panel (86662-4) | |
| - Removed line 2 in the 'FPAR 2.0 Data Elements' tab: 'Family Planning Annual Report PANEL.' This was removed as a result of LOINC no longer creating panels; the current Family Planning Annual Report PANEL (86636-8) will no longer be supported or updated. | |
| - Removed column C in the 'FPAR 2.0 Data Elements' tab: 'In FPAR Panel?' This was removed as a result of LOINC no longer creating panels; the current Family Planning Annual Report PANEL (86636-8) will no longer be supported or updated. | |
| - Added new tab 'Syphilis Tests Panel' tab containing the LOINC codes and links to the 57 identified Syphilis tests for possible use in FPAR 2.0. Please note that LOINC is no longer creating value sets of codes (collections structured under a LOINC panel code) for a specific use-cases and therefore this collection of Syphilis codes will not have a single panel code available. | |
| - Update to #9: Updated 'Ethnicity' to 'Ethnicity OMB.1997' to align with LOINC | |
| - Update to #21: Updated 'How Birth Control Method was Provided' to 'How Contraception Method was Provided' to align with LOINC | |
| - Removed term descriptions from #24 'Systolic Blood Pressure', #25: 'Diastolic Blood Pressure', #26: 'Body Height', #27: 'Body Weight' to align with LOINC | |
| - Added hyperlinks to all test LOINC codes across the six panels (86662-4, 86658-2, 86659-0, 86660-8, 86661-6, 86657-4) | |
| - Update to FPAR 2.0 Data Element (Long Common Name) in 'Pap Smear Tests Panel' (86662-4) to align with LOINC | |
| - Added available answer list/result values and answer list/result codes to the 'PAP Smear Tests Panel' (86662-4) | |
| - Update to use of 'Not Applicable' and '-' throughout. 'Not Applicable' is utilized in instances where it is not possible to have that information made available (i.e. Answer Lists: not all terms will have an answer list; some are open responses). A '-' is utilized in instances where that information could be made available but is not (i.e. Term Descriptions: all terms could have a description but not all have one available in LOINC) | |
| Version: 12/1/2021 | |
- Update to #7: Revised data element 'Sex' (LOINC 46098-0) to 'Sex assigned at birth' (76689-9) to align with United States Core Data for Interoperability (USCDI) standards. The following response options have been added: 'Unknown', 'Other', 'Asked, but Unknown', and 'Not Asked' |
|
- Added #8: Added data element 'Gender Identity' to align with United States Core Data for Interoperability (USCDI) standards |
|
- Added #9: Added data element 'Sexual Orientation' to align with United States Core Data for Interoperability (USCDI) standards |
|
- Renumbered data elements based on addition of #8 and #9 |
|
Sheet 2: READ ME
| 12/15/2021 Introduction The Family Planning Annual Report (FPAR) 2.0 Data Elements Excel table contains all data elements that have been identified and proposed by the Office of Population Affairs (OPA) for collection and reporting by Title X Grantees as part of FPAR 2.0. OPA will consider best practices for family planning, feedback from grantees, and reporting burden when making future modifications to the data element list. This page provides an overview of the content found on each tab in the Data Elements Excel table, and instructions for using this document to facilitate FPAR 2.0 data collection and reporting. Visit OPA's site at: Family Planning Annual Report | HHS Office of Population Affairs for additional information about FPAR 2.0 as needed: |
| https://opa.hhs.gov/research-evaluation/title-x-services-research/family-planning-annual-report/fpar2 |
Background Data Elements There are 43 data elements for the calendar year 2022 reporting period. The tabs in this file display the data elements, accompanied by their respective standard terminology code system, references for their supporting value set, and codes where available. OPA is limited in its ability to make edits to this standard terminology as they are often used by many other organizations and health systems. This technical document provides electronic health record (EHR) vendors and IT departments standard codes to support precise data identification and reporting. |
Standard Terminologies The two most commonly utilized standard terminologies to support reporting of the FPAR 2.0 data set are Logical Observation Identifiers Names and Codes (LOINC) and Systematic Nomenclature of Medicine Clinical Terms (SNOMED CT). LOINC and SNOMED work together to provide a common framework for identifying and exchanging FPAR 2.0 data. - Logical Observation Identifiers Names and Codes (LOINC) – Consists of codes for observations made on patients and populations. - Systematic Nomenclature of Medicine Clinical Terms (SNOMED CT) - Consists of concepts, terms, and relationships that enable effective representation of clinical information. In summary, LOINC codes ask the questions (what is it that you are observing?) and SNOMED CT codes provide the potential answer options for what you’ve observed. However, not all observations have a defined answer list/value set. For a quantitative data element, such as 'Systolic Blood Pressure', a numerical value is to be reported. |
Description of Data Element Tabs The information below explains content within each tab of the Data Element file |
FPAR 2.0 Data Elements |
FPAR 2.0 Data Element (Long Common Name) (Column B) This column identifies and names each of the elements to be reported. The names directly correspond to the LOINC Long Common Name (LCN). The LCN is the human readable name that accompanies each LOINC term. Please note that for the following data elements, the data element name used in the FPAR 2.0 data element file are different from the LCN of the code. In these instances, the name in the FPAR 2.0 Data Element column is modified in an effort to apply user friendly terms applicable to family planning encounters. |
A table containing a sub-set of FPAR 2.0 data elements, in which the data element name used in the FPAR 2.0 data element file differs from that of the LCN of the code. In these instances, then name in the FPAR 2.0 Data Element column is modified to apply user friendly terms applicable to family planning encounters.
|
| More specific information about the term is available through its multi-part LOINC Fully-Specified Name (FSN), found on the webpage linked from the ‘Data Element Code’ column of each data element. We have chosen the use of the LCN because it is more easily understood by a wider audience. Often, the FSN is harder to interpret but provides much more detail about what is being observed. |
Data Element Code (If Available) (Column C) Where available, the codes listed and linked to in this column correspond to the data elements named in Column B. Report these codes to represent the data element. These codes are for computer readability and removes ambiguity when producing the annual reports. |
Standard Terminology Code System (Column D) This column lists the standard terminology system to which the listed data element and code are located. For more information, refer to the section on Standard Terminologies above. |
Term Description (Column E) Where available, this column provides a description for each data element. This description has been pulled directly from the published standard terminology code system, most often LOINC. These descriptions help to provide further information regarding the intended use of the code in data collection and reporting. |
Value Set/Answer List Name (Column F) This column contains the name of the value set or answer list that contains the possible coded result values/answers/response options for the data element, where available. Like the term’s LCN, this column provides the Answer List Name/Description exactly as it is listed in LOINC. This is the human readable name that accompanies each answer list. |
Response Descriptions (Column G) This column lists descriptions for acceptable answers/result values contained within the selected answer list. As previously described, not all data elements will have a coordinating answer list or result values. For example, a data element may be quantitative and will have a numerical value reported. In this case, ‘Not applicable’ is listed. Additionally, answer lists may represent the possible answers/result values for more than one data element. For example, the example answer list LL365-8 contains the answers 'Yes' and 'No' and is utilized with multiple data elements. |
Expected Codes/Values (Column H) Where available, entries in this column provide a link to codes for expected responses for each data element listed in column B. |
Value Set OID (If applicable) (Column I) An OID is utilized by ISO (International Organization for Standardization) and is a string of numbers that uniquely identifies the object. In this case, value set OIDs are displayed in this column, where available. Implementers may find it useful to reference the value set OID in the Value Set Authority Center to identify the response options and codes within the value set. |
Panels for Laboratory Tests Panels are also utilized to identify potential results of performed lab tests. These panels are listed on the main tab (FPAR 2.0 Data Elements), and full details for each panel are displayed in a separate tab, per panel (Pap tests, HPV tests, Chlamydia tests, Gonorrhea tests, HIV tests, and Syphilis tests). There is also a panel for Chlamydia Trachomatis and Neisseria Gonorrhoeae combined tests. Grantees are expected to report both the 'Data Element Code' (to identify the specific test ordered) and the 'Expected Codes/Values' (to identify the result) associated with each test. |
A Note on ‘Not Applicable’ and ‘–’ Throughout 'Not Applicable' is utilized in instances where it is not possible to have that information made available (i.e. Answer Lists: not all terms will have an answer list; some are open responses). A '-' is utilized in instances where that information could be made available but is not (i.e. Term Descriptions: all terms could have a description but not all have one available in LOINC). |
| End of worksheet |
Sheet 3: FPAR 2.0 Data Elements
| blank row | |||||||||||
| Data Element # | FPAR 2.0 Data Element (Long Common Name) |
Data Element Code (If Available) |
Standard Terminology Code System | Term Description | Value Set/Answer List Name | Response Descriptions | Expected Codes/Values | Value Set OID (If applicable) | Notes | eCQM | Modified Contraceptive Care Measures |
| 1 | Facility Identifier | 75524-9 | LOINC | A code that identifies a hospital or clinic. The facility ID may be a true identifier (e.g. Facility NPI) or a pseudo-identifier. | Not applicable | Not applicable | Not applicable | - | OPA intends to collect NPI 2, when possible. Further guidance to be developed | x | x |
| 2 | Attending physician NPI Provider | 68468-8 | LOINC | - | NPI / National Provider Identifier - NPI | Not applicable (However, answer list code provided because code is normative) |
LL512-5 | - | - | x | x |
| 3 | Provider Role | 86637-6 | LOINC | The role of the clinical provider (e.g. doctor, registered nurse) that provided services at the encounter. | Provider role / Example list of provider role types | Doctor Registered Nurse Midwife Nurse Practitioner Physician Assistant Physical Therapist Physical Therapist Assistant Other Student Physical therapist Student Physical therapy assistant |
LL4575-8 | 2.16.840.1.113762.1.4.1166.24 | - | - | x |
| 4 | Patient Identifier | 76435-7 | LOINC | The patient identifier is a unique alphanumeric string that identifies a specific patient and is assigned by a specific organization (the assigning authority) that should be reported using [LOINC: 76698-0]. In HL7 v2 messages, the patient identifier is reported in PID-3.1 and the assigning authority in PID-3.4. Examples of patient identifiers are medical record number, driver's license number and Social Security number, and their corresponding assigning authorities are the appropriate healthcare facility, state motor vehicle administration and the Social Security Administration, respectively. | Not applicable | Not applicable | Not applicable | - | OPA will NOT collect identifiers such as social security number or driver's license number. | x | x |
| 5 | Visit Date | 76427-4 | LOINC | - | Not applicable | Not applicable | Not applicable | - | - | x | x |
| 6 | Birth Date | 21112-8 | LOINC | - | Not applicable | Not applicable | Not applicable | - | - | x | x |
| 7 | Sex | 46098-0 | LOINC | In LOINC, sex refers to the biological sex of an organism, which is most commonly determined based on anatomy and physiology or genetic (chromosome) analysis. Our definition is based on the World Health Organization's definition of sex and gender: sex (male, female) refers to biological and physiological characteristics, and gender (masculine, feminine) refers to socially constructed roles, behaviors, activities, and attributes. | Gender_M/F / Male=1, Female=2 | Male Female |
LL1-9 | 2.16.840.1.113883.1.11.1 | - | x | x |
| 8 | Gender Identity | 76691-5 | LOINC | This term was created for the U.S. Department of Health and Human Services (HHS) 2015 Edition Health Information Technology (Health IT) Certification Criteria final rule. [https://www.federalregister.gov/articles/2015/10/16/2015-25597/2015-edition-health-information-technology-health-it-certification-criteria-2015-edition-base] | Not applicable | Male Female Female-to-Male (FTM)/Transgender Male/Trans Male Male-to-female (MTF)/Transgender Female/Trans Woman Other Identifies as neither exclusively male nor female Choose not to disclose Unknown |
446151000124109 - SNOMEDCT 446141000124107 - SNOMEDCT 407377005 - SNOMEDCT 407376001 - SNOMEDCT OTH 446131000124102 - SNOMEDCT ASKU UNK |
1.3.6.1.4.1.12009.10.1.2156 2.16.840.1.114222.4.11.875 |
OID 1.3.6.1.4.1.12009.10.1.2156 - Gender Identity, includes the following responses: - 'Identifies as a male'; 'Identifies as a female'; 'Female-to-male transsexual'; 'Male-to-female transsexual'; 'Identifies as non-conforming' OID 2.16.840.1.114222.4.11.875- NULLFlavor (HL7 V3) includes the following responses: - 'Other'; 'Asked, but Unknown' NOTE: OID 1.3.6.1.4.1.12009.10.1.2156 corresponds to the answer list for LOINC 76691-5 See also United States Core Data for Interoperability (USCDI) for additional information about response options for Patient Demographics: https://www.healthit.gov/isa/united-states-core-data-interoperability-uscdi |
- | - |
| 9 | Sexual Orientation | 76690-7 | LOINC | This term was created for the U.S. Department of Health and Human Services (HHS) 2015 Edition Health Information Technology (Health IT) Certification Criteria final rule. [https://www.federalregister.gov/articles/2015/10/16/2015-25597/2015-edition-health-information-technology-health-it-certification-criteria-2015-edition-base] | Sexual orientation | Bisexual Lesbian, gay, or homosexual Straight or heterosexual Other, Something else Unknown Asked, but unknown |
42035005 - SNOMEDCT 38628009 - SNOMEDCT 20430005 - SNOMEDCT OTH UNK ASKU |
2.16.840.1.113762.1.4.1021.33 2.16.840.1.114222.4.11.875 |
OID 2.16.840.1.113762.1.4.1021.33 - Sexual Orientation, includes the following responses: - 'Bisexual'; 'Heterosexual'; 'Homosexual'; 'Sexually attracted to neither male nor female sex' OID 2.16.840.1.114222.4.11.875- NULLFlavor (HL7 V3) includes the following responses: - 'Other'; 'Asked, but Unknown'; 'Unknown' See also United States Core Data for Interoperability (USCDI) for additional information about response options for Patient Demographics: https://www.healthit.gov/isa/united-states-core-data-interoperability-uscdi |
- | - |
| 10 | Limited English Proficiency | 86640-0 | LOINC | This concept indicates whether the patient has limited English proficiency and may require care delivery in a language other than the English. | Proficient in English|Not proficient in English / Proficient or not proficient in English | Proficient in English Not Proficient in English |
LL4682-2 | 2.16.840.1.113762.1.4.1166.31 | - | - | - |
| 11 | Ethnicity OMB.1997 | 69490-1 | LOINC | This term is used for reporting the ethnicity based on classifications provided by the Office of Management and Budget (OMB), Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity (Oct. 30, 1997). | Ethnicity OMB 1997 / Answer list for ethnicity based on OMB 1997 Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity | Hispanic or Latino Not Hispanic or Latino |
LL2361-5 | 2.16.840.1.114222.4.11.837 | - | x | x |
| 12 | Race | 32624-9 | LOINC | Race as defined by the Office of Management and Budget (OMB). | Race or Unknown / OMB 1997 race categories plus Unknown | American Indian or Alaska Native Asian Black or African American Native Hawaiian or Other Pacific Islander White Unknown |
LL2858-0 | 2.16.840.1.113883.3.2074.1.1.3 | - | x | x |
| 13 | Annual Household Income | 63586-2 | LOINC | Estimate of gross family income in the past year | - | - | - | - | A discrete value is expected. Do not report an income range. | - | x |
| 14 | Household size [#] | 86639-2 | LOINC | Number in household; family is 1 person or 2 or more persons living together as a household. | Not applicable | Not applicable | Not applicable | - | - | - | x |
| 15 | Insurance Coverage Type | 87520-3 | LOINC | A high level description of a patient's health coverage type, including various categories of insurance (public, private, etc.) and self-pay. To report the specific source(s) of payment for a health care product or service, use Payment sources [LOINC: 52556-8]. | Coverage Type and Self-Pay Codes / A value set includes Coverage Type codes | Pay extended healthcare health spending account automobile collision coverage policy uninsured motorist policy public healthcare dental program public health program women's cancer detection program end renal program HIV-AIDS program mandatory health program mental health program safety net clinic program substance use program subsidized health program subsidized managed care program subsidized supplemental health program worker's compensation dental care policy disease specific policy drug policy health insurance plan policy long term care policy managed care policy point of service policy health maintenance organization policy preferred provider organization policy mental health policy substance use policy vision care policy disability insurance policy employee welfare benefit plan policy flexible benefit plan policy life insurance policy annuity policy term life insurance policy universal life insurance policy property and casualty insurance policy reinsurance policy surplus line insurance policy umbrella liability insurance policy charity program crime victim program employee assistance program government employee health program high risk pool program indigenous peoples health program military health program retiree health program social service program veteran health program |
LL4668-1 | 2.16.840.1.113762.1.4.1166.29 | - | - | x |
| 16 | Payer for visit | 52556-8 | LOINC | - | Coverage Type and Self-Pay Codes / A value set includes Coverage Type codes | None (no charge for current services) Medicare (traditional fee-for-service) Medicare (HMO/managed care) Medicaid (traditional fee-for-service) Medicaid (HMO/managed care) Workers’ compensation Title programs (e.g., Title III, V, or XX) Other government (e.g., TRICARE, VA, etc.) Private insurance/Medigap Private HMO/managed care Self-pay Other (specify) Unknown |
LL544-8 | 2.16.840.1.114222.4.11.3591 | - | - | x |
| 17 | Pregnancy Status | 82810-3 | LOINC | This term should be used to indicate that the patient is currently pregnant, not pregnant, or that the pregnancy status is unknown at this time. Depending on the context in which this term is used, there may be a need to capture more granular information. For example, further information such as whether the pregnancy is planned or unplanned and whether the status is patient reported or test confirmed may be necessary. | Pregnant|Not pregnant|Unknown / Answers: 3; Scale: Nom; Code: -; Score: - | Pregnant Not Pregnant Unknown |
LL4129-4 | 2.16.840.1.113762.1.4.1166.1 | - | x | x |
| 18 | Pregnancy Intention | 86645-9 | LOINC | A patient's intention or desire in the next year to either become pregnant or prevent a future pregnancy. This includes male patients seeking pregnancy with a female partner. Pregnancy intention may be used to help improve preconception health screenings and decisions, such as determining an appropriate contraceptive method, taking folic acid, or avoiding toxic exposures such as alcohol, tobacco and certain medications. | Yes|OK either way|No|Unsure / Answers: 4; Scale: Nom; Code: -; Score: - | Yes, I want to become pregnant I'm OK either way No, I don't want to become pregnant Unsure |
LL4053-6 | - | - | - | x |
| 19 | Contraceptive method at intake reported – at intake | 86649-1 | LOINC | At intake of patient encounter, their reported contraceptive method(s) used in the last sexual encounter. | Birth control methods / List of contraceptive methods | Implantable rod IUD with Progestin IUD copper IUD unspecified Female sterilization Vasectomy Injectables Combined oral contraceptive pills Progestin only contraceptive pills Contraceptive patch Vaginal ring Male condom Diaphragm or cervical cap Female condom Withdrawal Spermicide Sponge Fertility awareness-based methods Lactational amenorrhea method Male relying on female method Emergency contraception Decline to answer None |
LL4578-2 | 2.16.840.1.113762.1.4.1166.17 | Used for electronic clinical quality measure and modified contraceptive care measure calculations. More guidance to follow. | x | x |
| 20 | Reason for no contraceptive method use Reported – at intake | 86650-9 | LOINC | At intake of patient encounter, the reason the patient reported no contraceptive method used. | Reason for no birth control / Example list of reasons for why birth control (contraceptive methods) is not used | Abstinence Same sex partner Other Sterile for non-contraceptive reasons Seeking pregnancy |
LL4579-0 | 2.16.840.1.113762.1.4.1166.18 | Used for modified contraceptive care measure calculations. More guidance to follow. | - | x |
| 21 | Contraceptive method at exit reported – at exit | 86651-7 | LOINC | The contraceptive method(s) provided to or in use by the patient at the end of their visit after counseling and assessment by provider. | Birth control methods / List of contraceptive methods | Implantable rod IUD with Progestin IUD copper IUD unspecified Female sterilization Vasectomy Injectables Combined oral contraceptive pills Progestin only contraceptive pills Contraceptive patch Vaginal ring Male condom Diaphragm or cervical cap Female condom Withdrawal Spermicide Sponge Fertility awareness-based methods Lactational amenorrhea method Male relying on female method Emergency contraception Decline to answer None |
LL4578-2 | 2.16.840.1.113762.1.4.1166.17 | Similar to Table 7 in FPAR 1.0, continue to be reported in FPAR 2.0. Also used for the modified contraceptive care measure calculations. | x | x |
| 22 | Reason for no contraceptive method use reported – at exit | 86653-3 | LOINC | The reported reason at the end of the patient's visit for not using a contraceptive method(s). | Reason for no birth control / Example list of reasons for why birth control (contraceptive methods) is not used | Abstinence Same sex partner Other Sterile for non-contraceptive reasons Seeking pregnancy |
LL4579-0 | 2.16.840.1.113762.1.4.1166.18 | Similar to Table 7 in FPAR 1.0, continue to be reported in FPAR 2.0. Also used for the modified contraceptive care measure calculations. | - | x |
| 23 | How contraceptive method was provided | 86652-5 | LOINC | The method for how the birth control was provided (e.g. on site, referral, prescription) to the patient at end of an encounter. | Method for providing birth control / Example for how birth control method was provided to the patient | Provided on site Referral Prescription |
LL4580-8 | 2.16.840.1.113762.1.4.1166.21 | Used for modified contraceptive care measure calculations. More guidance to follow. | - | x |
| 24 | Contraceptive counseling was provided | 86654-1 | LOINC | Contraceptive counseling is an interaction in which provider spends time (5-10 minutes) during an encounter discussing the patient's choice of contraceptive method and available options. | [HL7-0136] Yes|No / Answers: 2; Scale: Ord; Code: Y-N; Score: - | Yes No |
LL365-8 | - | Used for modified contraceptive care measure calculations. More guidance to follow. | - | x |
| 25 | Counseling to achieve pregnancy was provided | 86655-8 | LOINC | Counseling to achieve pregnancy is an interaction in which a provider spends time during an encounter discussing any services and/or provides counseling related to achieving pregnancy or addressing infertility. | [HL7-0136] Yes|No / Answers: 2; Scale: Ord; Code: Y-N; Score: - | Yes No |
LL365-8 | - | Used for modified contraceptive care measure calculations. More guidance to follow. | - | x |
| 26 | Systolic blood pressure | 8480-6 | LOINC | - | Not applicable | Not applicable | Not applicable | - | - | - | - |
| 27 | Diastolic blood pressure | 8462-4 | LOINC | - | Not applicable | Not applicable | Not applicable | - | - | - | - |
| 28 | Body Height | 8302-2 | LOINC | - | Not applicable | Not applicable | Not applicable | - | - | - | - |
| 29 | Body Weight | 29463-7 | LOINC | - | Not applicable | Not applicable | Not applicable | - | - | - | - |
| 30 | Tobacco Smoking Status | 72166-2 | LOINC | Tobacco smoking status represents a person's smoking behavior. Smoking statuses can be classified as current every day smoker, current some day smoker, former smoker, never smoker, smoker - current status unknown, unknown if ever smoked, current heavy tobacco smoker, and current light tobacco smoker. These statuses represent CDC's preferred (sometimes required) responses for recording smoking status. | Smoking Status - HL7 Value Set / Value Set based on HL7 Vocab TC and Structured Doc consensus (per CDC submission 7/12/2012 for smoking status term) | Current every day smoker Current some day smoker Former smoker Never smoker Smoker, current status unknown Unknown if ever smoked Heavy tobacco smoker Light tobacco smoker |
LL2201-3 | 2.16.840.1.113883.11.20.9.38 | - | - | - |
| 31 | Pap test performed at this visit | - | - | A pap test was performed during the visit. | [HL7-0136] Yes|No / Answers: 2; Scale: Ord; Code: Y-N; Score: - | Yes No |
LL365-8 | - | - | - | - |
| 32 | Pap smear tests - FPAR 2.0 set (PANEL) | 86662-4 | LOINC | Set of lab terms that may be used to gather Pap smear test results at time of the patient encounter as specified by the Family Planning Annual Report (FPAR). | See corresponding tab | - | - | 2.16.840.1.113762.1.4.1166.10 | This data element is a panel set - see TAB 86662-4 | - | - |
| 33 | HPV test performed at this visit | - | - | An HPV test was performed during the visit. | [HL7-0136] Yes|No / Answers: 2; Scale: Ord; Code: Y-N; Score: - | Yes No |
LL365-8 | - | - | - | - |
| 34 | HPV tests - FPAR 2.0 set (PANEL) | 86658-2 | LOINC | Set of lab terms that may be used to gather HPV test results at time of the patient encounter as specified by the Family Planning Annual Report (FPAR). | See corresponding tab | - | - | 2.16.840.1.113762.1.4.1166.12 | This data element is a panel set - see TAB 86658-2 | - | - |
| 35 | Chlamydia sp test performed at this visit | - | - | A Chlamydia test was performed during the visit. | [HL7-0136] Yes|No / Answers: 2; Scale: Ord; Code: Y-N; Score: - | Yes No |
LL365-8 | - | - | - | - |
| 36 | Chlamydia sp tests - FPAR 2.0 set (PANEL) | 86659-0 | LOINC | Set of lab terms that may be used to gather Chlamydia trachomatis test results at time of the patient encounter as specified by the Family Planning Annual Report (FPAR). | See corresponding tab | - | - | 2.16.840.1.113762.1.4.1166.13 | This data element is a panel set - see TAB 86659-0 See TAB 86661-6 for panel of Chlamydia Trachomatis and Neisseria Gonorrhoeae combined tests |
- | - |
| 37 | Neisseria gonorrhoeae test performed at this visit | - | - | A Neisseria gonorrhoeae test was performed during the visit. | [HL7-0136] Yes|No / Answers: 2; Scale: Ord; Code: Y-N; Score: - | Yes No |
LL365-8 | - | - | - | - |
| 38 | Neisseria gonorrhoeae tests - FPAR 2.0 set (PANEL) | 86660-8 | LOINC | Set of lab terms that may be used to gather Neisseria gonorrhoeae test results at time of the patient encounter as specified by the Family Planning Annual Report (FPAR). | See corresponding tab | - | - | 2.16.840.1.113762.1.4.1166.14 | This data element is a panel set - see TAB 86660-8 See TAB 86661-6 for panel of Chlamydia Trachomatis and Neisseria Gonorrhoeae combined tests |
- | - |
| 39 | HIV test performed at this visit | - | - | An HIV test was performed during the visit. | [HL7-0136] Yes|No / Answers: 2; Scale: Ord; Code: Y-N; Score: - | Yes No |
LL365-8 | - | - | - | - |
| 40 | HIV 1 and 2 tests - FPAR 2.0 set (PANEL) | 86657-4 | LOINC | Set of lab terms that may be used to gather HIV 1 & 2 test results at time of the patient encounter as specified by the Family Planning Annual Report (FPAR). | See corresponding tab | - | - | 2.16.840.1.113762.1.4.1166.11 | This data element is a panel set - see TAB 86657-4 | - | - |
| 41 | Syphilis test performed at this visit | - | - | A Syphilis test was performed during the visit. | [HL7-0136] Yes|No / Answers: 2; Scale: Ord; Code: Y-N; Score: - | Yes No |
LL365-8 | - | - | - | - |
| 42 | Syphilis Test Result | - | - | - | - | - | - | 2.16.840.1.113762.1.4.1166.117 | This data element is a panel set - see TAB Syphilis Tests Panel | - | - |
| 43 | Do you want to talk about contraception or pregnancy prevention during your visit today | 98076-3 | LOINC | - | - | Yes No - I do not want to talk about contraception today because I am here for something else No - This question does not apply to me/I prefer not to answer No - I am already using contraception No - I am unsure or don't want to use contraception No - I am hoping to become pregnant in the near future |
LL5991-6 | - | OPTIONAL for reporting. Used for the electronic clinical quality measure (eCQM) calculation in development at UCSF under a grant from OPA (Self-identified need for contraception). A patient’s self-reported desire to discuss contraception at their visit. Can be asked to a person of any gender and should be asked minimum once per year. Can be asked alongside a patient's intention or desire in the next year to become pregnant. |
x | - |
Sheet 4: Pap Smear Tests Panel (86662-4)
| Table 2. Pap Smear Tests Panel (86662-4) | |||||||||
| blank row | |||||||||
| Data Element # | FPAR 2.0 Data Element (Long Common Name) |
In FPAR Panel? | Data Element Code (If Available) |
Standard Terminology Code System | Term Description | Value Set/Answer List Name | Response Descriptions | Expected Codes/Values | Notes |
| - | Pap smear tests - FPAR 2.0 set (PANEL) | Y | 86662-4 | LOINC | Set of lab terms that may be used to gather Pap smear test results at time of the patient encounter as specified by the Family Planning Annual Report (FPAR). | - | - | - | LOINC Panels are collections of LOINC terms that represent specific sets of information, such as a laboratory battery of tests, a group of findings from a procedure such as an EKG, and forms or assessments related to health that are completed by patients and/or providers. LOINC Panels contain a specific structure, and depending on the type of panel, can include attributes such as form coding instructions, skip logic, and nested panels. |
| 1 | Microscopic observation [Identifier] in Cervix by Cyto stain | Y | 10524-7 | LOINC | Microscopy is a technique that uses microscopes to examine very small objects, not seen by the naked eye. There are three well-known branches of microscopy: optical, electron and scanning probe microscopy. | - | ASCUS Atypical Squamous cells of undetermined significance, cannot exclude HGSIL ASCUS Atypical Squamous cells of undetermined significance Low Grade SIL High Grade SIL Squamous cell carcinoma Atypical glandular cells NOS Atypical glandular cells suspicious for cancer Adenocarcinoma in-situ negative for interepithelial lesion |
373878001 - SNOMEDCT 103637006 - SNOMEDCT 112662005 - SNOMEDCT 22725004 - SNOMEDCT 28899001 - SNOMEDCT 441219009 - SNOMEDCT 373883009 - SNOMEDCT 51642000 - SNOMEDCT 373887005 - SNOMEDCT |
- |
| 2 | Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep | Y | 18500-9 | LOINC | Thin prep is an automated method of preparing the smear;cells are first treated/lysed to diminish obstructions such as blood, then spread very thinly by the machine. | - | ASCUS Atypical Squamous cells of undetermined significance, cannot exclude HGSIL ASCUS Atypical Squamous cells of undetermined significance Low Grade SIL High Grade SIL Squamous cell carcinoma Atypical glandular cells NOS Atypical glandular cells suspicious for cancer Adenocarcinoma in-situ negative for interepithelial lesion |
373878001 - SNOMEDCT 103637006 - SNOMEDCT 112662005 - SNOMEDCT 22725004 - SNOMEDCT 28899001 - SNOMEDCT 441219009 - SNOMEDCT 373883009 - SNOMEDCT 51642000 - SNOMEDCT 373887005 - SNOMEDCT |
- |
| 3 | Microscopic observation [Identifier] in Cervical or vaginal smear or scraping by Cyto stain | Y | 19765-7 | LOINC | Microscopy is a technique that uses microscopes to examine very small objects, not seen by the naked eye. There are three well-known branches of microscopy: optical, electron and scanning probe microscopy. | - | ASCUS Atypical Squamous cells of undetermined significance, cannot exclude HGSIL ASCUS Atypical Squamous cells of undetermined significance Low Grade SIL High Grade SIL Squamous cell carcinoma Atypical glandular cells NOS Atypical glandular cells suspicious for cancer Adenocarcinoma in-situ negative for interepithelial lesion |
373878001 - SNOMEDCT 103637006 - SNOMEDCT 112662005 - SNOMEDCT 22725004 - SNOMEDCT 28899001 - SNOMEDCT 441219009 - SNOMEDCT 373883009 - SNOMEDCT 51642000 - SNOMEDCT 373887005 - SNOMEDCT |
- |
| 4 | Microscopic observation [Identifier] in Cervical or vaginal smear or scraping by Cyto stain Narrative | Y | 19766-5 | LOINC | Microscopy is a technique that uses microscopes to examine very small objects, not seen by the naked eye. There are three well-known branches of microscopy: optical, electron and scanning probe microscopy. | - | - | - | - |
| 5 | Cytology study comment Cervical or vaginal smear or scraping Cyto stain | Y | 19774-9 | LOINC | - | - | ASCUS Atypical Squamous cells of undetermined significance, cannot exclude HGSIL ASCUS Atypical Squamous cells of undetermined significance Low Grade SIL High Grade SIL Squamous cell carcinoma Atypical glandular cells NOS Atypical glandular cells suspicious for cancer Adenocarcinoma in-situ negative for interepithelial lesion |
373878001 - SNOMEDCT 103637006 - SNOMEDCT 112662005 - SNOMEDCT 22725004 - SNOMEDCT 28899001 - SNOMEDCT 441219009 - SNOMEDCT 373883009 - SNOMEDCT 51642000 - SNOMEDCT 373887005 - SNOMEDCT |
- |
| 6 | Cytology Cervical or vaginal smear or scraping study | Y | 33717-0 | LOINC | Document that is generated in response to a request. | - | - | - | - |
| 7 | Cytology report of Cervical or vaginal smear or scraping Cyto stain.thin prep | Y | 47527-7 | LOINC | - | - | ASCUS Atypical Squamous cells of undetermined significance, cannot exclude HGSIL ASCUS Atypical Squamous cells of undetermined significance Low Grade SIL High Grade SIL Squamous cell carcinoma Atypical glandular cells NOS Atypical glandular cells suspicious for cancer Adenocarcinoma in-situ negative for interepithelial lesion |
373878001 - SNOMEDCT 103637006 - SNOMEDCT 112662005 - SNOMEDCT 22725004 - SNOMEDCT 28899001 - SNOMEDCT 441219009 - SNOMEDCT 373883009 - SNOMEDCT 51642000 - SNOMEDCT 373887005 - SNOMEDCT |
- |
| 8 | Cytology report of Cervical or vaginal smear or scraping Cyto stain | Y | 47528-5 | LOINC | - | - | ASCUS Atypical Squamous cells of undetermined significance, cannot exclude HGSIL ASCUS Atypical Squamous cells of undetermined significance Low Grade SIL High Grade SIL Squamous cell carcinoma Atypical glandular cells NOS Atypical glandular cells suspicious for cancer Adenocarcinoma in-situ negative for interepithelial lesion |
373878001 - SNOMEDCT 103637006 - SNOMEDCT 112662005 - SNOMEDCT 22725004 - SNOMEDCT 28899001 - SNOMEDCT 441219009 - SNOMEDCT 373883009 - SNOMEDCT 51642000 - SNOMEDCT 373887005 - SNOMEDCT |
- |
| 9 | General categories [Interpretation] of Cervical or vaginal smear or scraping by Cyto stain | Y | 19762-4 | LOINC | - | - | ASCUS Atypical Squamous cells of undetermined significance, cannot exclude HGSIL ASCUS Atypical Squamous cells of undetermined significance Low Grade SIL High Grade SIL Squamous cell carcinoma Atypical glandular cells NOS Atypical glandular cells suspicious for cancer Adenocarcinoma in-situ negative for interepithelial lesion |
373878001 - SNOMEDCT 103637006 - SNOMEDCT 112662005 - SNOMEDCT 22725004 - SNOMEDCT 28899001 - SNOMEDCT 441219009 - SNOMEDCT 373883009 - SNOMEDCT 51642000 - SNOMEDCT 373887005 - SNOMEDCT |
- |
| 10 | Statement of adequacy [Interpretation] of Cervical or vaginal smear or scraping by Cyto stain | Y | 19764-0 | LOINC | - | - | Speciman satisfactory for evaluation Speciman Unsatisfactory for evaluation |
125152006 - SNOMEDCT 125154007 - SNOMEDCT |
- |
| End of worksheet |
Sheet 5: HPV Tests Panel (86658-2)
| Table 3. HPV Tests Panel (86658-2) | |||||||||
| blank row | |||||||||
| Data Element # | FPAR 2.0 Data Element (Long Common Name) |
In FPAR Panel? | Data Element Code (If Available) |
Standard Terminology Code System | Term Description | Value Set/Answer List Name | Response Descriptions | Expected Codes/Values | Notes |
| - | HPV tests - FPAR 2.0 set (PANEL) | Y | 86658-2 | LOINC | Set of lab terms that may be used to gather HPV test results at time of the patient encounter as specified by the Family Planning Annual Report (FPAR). | - | - | - | LOINC Panels are collections of LOINC terms that represent specific sets of information, such as a laboratory battery of tests, a group of findings from a procedure such as an EKG, and forms or assessments related to health that are completed by patients and/or providers. LOINC Panels contain a specific structure, and depending on the type of panel, can include attributes such as form coding instructions, skip logic, and nested panels. |
| 1 | Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+66+68 DNA [Presence] in Cervix by Probe with signal amplification | Y | 59420-0 | LOINC | Common high-risk HPV genotypes associated with cervical neoplasia can be detected by genomic probes. This code is based on, but not limited in use to, the submitter's assay INFORM HPV III Family 16 Probe (B), which contains a cocktail of HPV genomic probes targeting DNA from 12 high-risk genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66). | Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+66+68 DNA [Presence] in Cervix by Probe with signal amplification | Detected (qualifier value) Not detected (qualifier value) |
LL744-4 260373001 - SNOMEDCT 260415000 - SNOMEDCT |
- |
| 2 | Human papilloma virus 16+18+31+33+35+45+51+52+56 DNA [Presence] in Cervix by Probe | Y | 21440-3 | LOINC | HPV 6 11 42 43 & 44=Low Risk; HPV 16 18 31 33 35 45 51 52 & 56= Intermediate/High Risk | Pos|Neg / Answers: 2; Scale: Ord; Code: -; Score: - | Positive (qualifier value) Negative (qualifier value) |
LL360-9 10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- |
| 3 | Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA [Presence] in Cervix by Probe with signal amplification | Y | 30167-1 | LOINC | - | - | Positive (qualifier value) Negative (qualifier value) |
10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- |
| 4 | Human papilloma virus 6+11+16+18+31+33+35+39+42+43+44+45+51+52+56+58+59+68 DNA [Presence] in Cervix by Probe with signal amplification | Y | 38372-9 | LOINC | - | Pos|Neg / Answers: 2; Scale: Ord; Code: -; Score: - | Positive (qualifier value) Negative (qualifier value) |
LL360-9 10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- |
| 5 | Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA [Presence] in Unspecified specimen by NAA with probe detection | Y | 49896-4 | LOINC | - | Pos|Neg / Answers: 2; Scale: Ord; Code: -; Score: - | Positive (qualifier value) Negative (qualifier value) |
LL360-9 10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- |
| 6 | Human papilloma virus E6+E7 mRNA [Presence] in Cervix by NAA with probe detection | Y | 69002-4 | LOINC | This term was created for (but not limited to) Gen-Probe's Aptima HPV assay (Cat No. 302610) that detects the E6 and E7 polycistronic mRNA from 14 high-risk HPV genotypes (16,18,31,33,35,39,45,51,52,56,58,59,66,and 68) that can lead to cervical cancer. E6/E7 genes in high-risk HPV genotypes are known as oncogenes because of their continuous expression, which leads to disruption of cell-cycle check points and cell genome instability through alteration of cellular p53 and retinoblastoma protein functions. This test is similar to LOINC 69358-0, which measures cells containing E6+E7 mRNA via flow cytometry. | Pos|Neg / Answers: 2; Scale: Ord; Code: -; Score: - | Positive (qualifier value) Negative (qualifier value) |
LL360-9 10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- |
| 7 | Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+66 DNA [Presence] in Tissue by Probe | Y | 73959-9 | LOINC | Common high-risk HPV genotypes associated with cervical neoplasia can be detected by genomic probes. This code is based on, but not limited in use to, the submitter's assay INFORM HPV III Family 16 Probe (B), which contains a cocktail of HPV genomic probes targeting DNA from 12 high-risk genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66). | Pos|Neg / Answers: 2; Scale: Ord; Code: -; Score: - | Positive (qualifier value) Negative (qualifier value) |
LL360-9 10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- |
| 8 | Human papilloma virus identified in Cervix | Y | 11083-3 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 9 | Human papilloma virus 16+18 Ag [Presence] in Genital specimen | Y | 12223-4 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 10 | Human papilloma virus 16+18 Ag [Presence] in Cervix | Y | 14503-7 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 11 | Human papilloma virus 16+18 Ag [Presence] in Vaginal fluid | Y | 14504-5 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 12 | Human papilloma virus 16+18 Ag [Presence] in Urethra | Y | 14506-0 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 13 | Human papilloma virus 16+18 Ag [Presence] in Specimen | Y | 17400-3 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 14 | Human papilloma virus DNA [Presence] in Cervix by Probe | Y | 44550-2 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 15 | Human papilloma virus rRNA [Presence] in Genital specimen by NAA with probe detection | Y | 6514-4 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 16 | Human papilloma virus rRNA [Presence] in Specimen by NAA with probe detection | Y | 6516-9 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| End of worksheet |
Sheet 6: Chlamydia Tests Panel (86659-0)
| Table 4. Chlamydia Tests Panel (86659-0) | |||||||||
| blank row | |||||||||
| Data Element # | FPAR 2.0 Data Element (Long Common Name) |
In FPAR Panel? | Data Element Code (If Available) |
Standard Terminology Code System | Term Description | Value Set/Answer List Name | Response Descriptions | Expected Codes/Values | Notes |
| - | Chlamydia sp tests - FPAR 2.0 set (PANEL) | Y | 86659-0 | LOINC | Set of lab terms that may be used to gather Chlamydia trachomatis test results at time of the patient encounter as specified by the Family Planning Annual Report (FPAR). | - | - | - | LOINC Panels are collections of LOINC terms that represent specific sets of information, such as a laboratory battery of tests, a group of findings from a procedure such as an EKG, and forms or assessments related to health that are completed by patients and/or providers. LOINC Panels contain a specific structure, and depending on the type of panel, can include attributes such as form coding instructions, skip logic, and nested panels. |
| 1 | Chlamydia trachomatis DNA [Units/volume] in Specimen by NAA with probe detection | Y | 49096-1 | LOINC | - | - | Not applicable Quantitative lab |
Not applicable | - |
| 2 | Chlamydia trachomatis rRNA [Presence] in Unspecified specimen by NAA with probe detection | Y | 43304-5 | LOINC | - | Chlamydia trachomatis rRNA [Presence] in Specimen by NAA with probe detection | Detected (qualifer value) Not Detected (qualifer value) Inconclusive (qualifer value) Equivocal (qualifer value) |
LL956-4 260373001 - SNOMEDCT 260415000 - SNOMEDCT 419984006 - SNOMEDCT 42425007 - SNOMEDCT |
- |
| 3 | Chlamydia trachomatis DNA [Presence] in Urethra by NAA with probe detection | Y | 21191-2 | LOINC | - | Pos|Neg / Answers: 2; Scale: Ord; Code: -; Score: - | Positive (qualifier value) Negative (qualifier value) |
LL360-9 10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- |
| 4 | Chlamydia trachomatis rRNA [Presence] in Unspecified specimen by Probe | Y | 4993-2 | LOINC | 3 subspecies cause LGV | - | Positive (qualifier value) Negative (qualifier value) |
10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- |
| 5 | Chlamydia trachomatis rRNA [Presence] in Genital specimen by Probe | Y | 16600-9 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 6 | Chlamydia trachomatis rRNA [Presence] in Urine by Probe | Y | 16601-7 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 7 | Chlamydia trachomatis DNA [Presence] in Cervical mucus by NAA with probe detection | Y | 21189-6 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 8 | Chlamydia trachomatis DNA [Presence] in Cervix by NAA with probe detection | Y | 21190-4 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 9 | Chlamydia trachomatis rRNA [Presence] in Urethra by Probe | Y | 21192-0 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 10 | Chlamydia trachomatis DNA [Presence] in Unspecified specimen by NAA with probe detection | Y | 21613-5 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 11 | Chlamydia trachomatis rRNA [Presence] in Genital fluid by Probe | Y | 23838-6 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 12 | Chlamydia sp DNA [Presence] in Unspecified specimen by NAA with probe detection | Y | 35729-3 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 13 | Chlamydia trachomatis rRNA [Presence] in Urine by NAA with probe detection | Y | 42931-6 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 14 | Chlamydia trachomatis DNA [Presence] in Unspecified specimen by Probe with signal amplification | Y | 43404-3 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 15 | Chlamydia trachomatis rRNA [Presence] in Cervix by Probe | Y | 45078-3 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 16 | Chlamydia trachomatis rRNA [Presence] in Vaginal fluid by Probe | Y | 45080-9 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 17 | Chlamydia trachomatis DNA [Presence] in Vaginal fluid by NAA with probe detection | Y | 45084-1 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 18 | Chlamydia trachomatis L2 DNA [Presence] in Unspecified specimen by NAA with probe detection | Y | 47211-8 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 19 | Chlamydia trachomatis DNA [Identifier] in Unspecified specimen by NAA with probe detection | Y | 47212-6 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 20 | Chlamydia trachomatis rRNA [Presence] in Cervix by NAA with probe detection | Y | 50387-0 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 21 | Chlamydia trachomatis rRNA [Presence] in Urethra by NAA with probe detection | Y | 53925-4 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 22 | Chlamydia trachomatis rRNA [Presence] in Vaginal fluid by NAA with probe detection | Y | 53926-2 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 23 | Chlamydia trachomatis DNA [Presence] in Genital specimen by NAA with probe detection | Y | 6356-0 | LOINC | 3 subspecies cause LGV | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 24 | Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection | Y | 6357-8 | LOINC | 3 subspecies cause LGV | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| End of worksheet |
Sheet 7: Neis. Gonorrhea Panel (86660-8)
| Table 5. Neis. Gonorrhea Panel (86660-8) | |||||||||
| blank row | |||||||||
| Data Element # | FPAR 2.0 Data Element (Long Common Name) |
In FPAR Panel? | Data Element Code (If Available) |
Standard Terminology Code System | Term Description | Value Set/Answer List Name | Response Descriptions | Expected Codes/Values | Notes |
| - | Neisseria Gonorrhoeae Tests - FPAR 2.0 set | Y | 86660-8 | LOINC | Set of lab terms that may be used to gather Neisseria gonorrhoeae test results at time of the patient encounter as specified by the Family Planning Annual Report (FPAR). | - | - | - | - |
| 1 | Neisseria gonorrhoeae rRNA [Presence] in Unspecified specimen by NAA with probe detection | Y | 43305-2 | LOINC | Neisseria gonorrhoeae are gram-negative cocci usually seen in pairs with the adjacent sides flattened. Pili, filament-like appendages, extend from the cell surface and have a role in adherence. Gonorrhea is usually acquired by sexual contact. Men and women aged 15-29 have the highest incidence of gonorrhea. Number of sexual partners, sexual practices and preference, condom use and population mobility contribute to disease incidence. The most frequent sites are the cervix, urethra, rectum, pharynx and conjunctiva. The most common symptom in men is discharge that may be scanty and clear or cloudy to copious and purulent, and often dysuria. Asymptomatic men are an important reservoir for transmission. Endocervical infection is the most common form of infection in women. Ocular infections occur most commonly in newborns who are exposed in the birth canal and can lead to corneal scarring or perforation. Gonococcal bacteremia may lead to disseminated infection including pelvic inflammatory disease in as many as 15 percent of women, leading to an increased probability of infertility and ectopic pregnancy. While antibiotics have successfully treated gonorrhea for decades, N. gonorrhoeae has developed antimicrobial resistance to every drug used for treatment. The Centers for Disease Control and Prevention recommends combination therapy using two antimicrobials with different mechanisms of action (e.g., a cephalosporin plus azithromycin) to improve treatment efficacy and potentially slow the spread of resistance to cephalosporins. [NCBI Books:NBK7650] [CDC:std/tg2015/gonorrhea] | Detected|Not det|Equiv|Inconcl / Answers: 4; Scale: Ord; Code: -; Score: - | Detected (qualifer value) Not Detected (qualifer value) Inconclusive (qualifer value) Equivocal (qualifer value) |
LL956-4 260373001 - SNOMEDCT 260415000 - SNOMEDCT 419984006 - SNOMEDCT 42425007 - SNOMEDCT |
- |
| 2 | Neisseria gonorrhoeae DNA [Presence] in Urethra by NAA with probe detection | Y | 21415-5 | LOINC | - | Pos|Neg / Answers: 2; Scale: Ord; Code: -; Score: - | Positive (qualifier value) Negative (qualifier value) |
LL360-9 10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- |
| 3 | Neisseria gonorrhoeae DNA [Presence] in Genital specimen by NAA with probe detection | Y | 47387-6 | LOINC | - | Pos|Neg / Answers: 2; Scale: Ord; Code: -; Score: - | Positive (qualifier value) Negative (qualifier value) |
LL360-9 10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- |
| 4 | Neisseria gonorrhoeae rRNA [Presence] in Cervix by NAA with probe detection | Y | 50388-8 | LOINC | - | Pos|Neg / Answers: 2; Scale: Ord; Code: -; Score: - | Positive (qualifier value) Negative (qualifier value) |
LL360-9 10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- |
| 5 | Neisseria gonorrhoeae DNA [Presence] in Cervical mucus by NAA with probe detection | Y | 21414-8 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 6 | Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection | Y | 21416-3 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 7 | Neisseria gonorrhoeae DNA [Presence] in Unspecified specimen by NAA with probe detection | Y | 24111-7 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 8 | Neisseria gonorrhoeae rRNA [Presence] in Cervix by Probe | Y | 32198-4 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 9 | Neisseria gonorrhoeae rRNA [Presence] in Urethra by Probe | Y | 32199-2 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 10 | Neisseria gonorrhoeae DNA [Presence] in Vaginal fluid by NAA with probe detection | Y | 32705-6 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 11 | Neisseria gonorrhoeae DNA [Presence] in Unspecified specimen by Probe with signal amplification | Y | 43403-5 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 12 | Neisseria gonorrhoeae rRNA [Presence] in Unspecified specimen by Probe | Y | 5028-6 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 13 | Neisseria gonorrhoeae rRNA [Presence] in Vaginal fluid by NAA with probe detection | Y | 53879-3 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 14 | Neisseria gonorrhoeae rRNA [Presence] in Urethra by NAA with probe detection | Y | 53927-0 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 15 | Neisseria gonorrhoeae Ag [Presence] in Genital specimen by Immunoassay | Y | 6487-3 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 16 | Neisseria gonorrhoeae [Presence] in Cervix by Organism specific culture | Y | 688-2 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 17 | Neisseria gonorrhoeae [Presence] in Genital specimen by Organism specific culture | Y | 691-6 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 18 | Neisseria gonorrhoeae [Presence] in Genital lochia by Organism specific culture | Y | 692-4 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 19 | Neisseria gonorrhoeae [Presence] in Vaginal fluid by Organism specific culture | Y | 693-2 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 20 | Neisseria gonorrhoeae [Presence] in Unspecified specimen by Organism specific culture | Y | 698-1 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| End of worksheet |
Sheet 8: CT+NG Com Tests Panel (86661-6)
| Table 6. CT+NG Com Tests Panel (86661-6) | |||||||||
| blank row | |||||||||
| Data Element # | FPAR 2.0 Data Element (Long Common Name) |
In FPAR Panel? | Data Element Code (If Available) |
Standard Terminology Code System | Term Description | Value Set/Answer List Name | Response Descriptions | Expected Codes/Values | Notes |
| - | Chlamydia trachomatis+Neisseria gonorrhoeae tests - FPAR 2.0 set | Y | 86661-6 | LOINC | Set of lab terms that may be used to gather Chlamydia trachomatis and Neisseria gonorrhoeae combined test results at time of the patient encounter as specified by the Family Planning Annual Report (FPAR). | - | - | - | LOINC Panels are collections of LOINC terms that represent specific sets of information, such as a laboratory battery of tests, a group of findings from a procedure such as an EKG, and forms or assessments related to health that are completed by patients and/or providers. LOINC Panels contain a specific structure, and depending on the type of panel, can include attributes such as form coding instructions, skip logic, and nested panels. |
| 1 | Chlamydia trachomatis+Neisseria gonorrhoeae DNA [Presence] in Unspecified specimen by NAA with probe detection | Y | 36902-5 | LOINC | - | Detected|Not det / Answers: 2; Scale: Ord; Code: -; Score: - | Detected (qualifier value) Not detected (qualifier value) |
LL744-4 260373001 - SNOMEDCT 260415000 - SNOMEDCT |
- |
| 2 | Chlamydia trachomatis and Neisseria gonorrhoeae DNA [Identifier] in Unspecified specimen by NAA with probe detection | Y | 36903-3 | LOINC | - | CT&GC probe / Clamydia trachomatis & Neisseria probe | Chlamydia trachomatis detected Chlamydia trachomatis not detected Chlamydia trachomatis inconclusive Chlamydia trachomatis equivocal Neisseria gonorrhoeae detected Neisseria gonorrhoeae not detected Neisseria gonorrhoeae inconclusive Neisseria gonorrhoeae equivocal Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
LL1501-7 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 3 | Chlamydia trachomatis+Neisseria gonorrhoeae DNA [Presence] in Unspecified specimen by Probe with signal amplification | Y | 43406-8 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 4 | Chlamydia trachomatis+Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection | Y | 6357-8 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 5 | Chlamydia trachomatis+Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection | Y | 44807-6 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 6 | Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Cervix by Probe | Y | 45067-6 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 7 | Chlamydia trachomatis+Neisseria gonorrhoeae DNA [Presence] in Cervix by NAA with probe detection | Y | 45068-4 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 8 | Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Genital specimen by Probe | Y | 45069-2 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 9 | Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Vaginal fluid by Probe | Y | 45070-0 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 10 | Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Urine by Probe | Y | 45074-2 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| 11 | Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Unspecified specimen by Probe | Y | 45076-7 | LOINC | - | - | Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- |
| End of worksheet |
Sheet 9: HIV 1 & 2 Tests Panel (86657-4)
| Table 7. HIV 1 & 2 Tests Panel (86657-4) | |||||||||||
| blank row | |||||||||||
| Data Element # | FPAR 2.0 Data Element (Long Common Name) |
HIV Test Type | In FPAR Panel? | Data Element Code (If Available) |
Standard Terminology Code System | Term Description | Value Set/Answer List Name | Response Descriptions | Expected Codes/Values | Binding to Answer List/Result Values | Notes |
| - | HIV 1 and 2 tests - FPAR 2.0 set (PANEL) | - | Y | 86657-4 | LOINC | Set of lab terms that may be used to gather HIV 1 & 2 test results at time of the patient encounter as specified by the Family Planning Annual Report (FPAR). | - | - | - | - | LOINC Panels are collections of LOINC terms that represent specific sets of information, such as a laboratory battery of tests, a group of findings from a procedure such as an EKG, and forms or assessments related to health that are completed by patients and/or providers. LOINC Panels contain a specific structure, and depending on the type of panel, can include attributes such as form coding instructions, skip logic, and nested panels. |
| 1 | HIV 1 RNA [Presence] in Unspecified specimen by NAA with probe detection | Supplemental/Confirmatory HIV test | Y | 5018-7 | LOINC | - | - | Detected (qualifier value) Not detected (qualifier value) Indeterminate (qualifer value) |
260373001 - SNOMEDCT 260415000 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 2 | HIV 1 Ab [Presence] in Serum by Immunoblot (IB) | Supplemental/Confirmatory HIV test | Y | 5221-7 | LOINC | - | - | Positive (qualifier value) Negative (qualifier value) Inconclusive (qualifer value) Equivocal (qualifer value) |
10828004 - SNOMEDCT 260385009 - SNOMEDCT 419984006 - SNOMEDCT 42425007 - SNOMEDCT |
- | - |
| 3 | HIV 1 Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | Rapid/Screening HIV test | Y | 68961-2 | LOINC | This term is intended to encode test results obtained within minutes. An example is the bioLytical INSTI HIV-1 kit, which can be used on serum, plasma, or whole blood, including fingerstick. At the time of creation, only the HIV-1 test is approved for use in the US, although an HIV-2 test is available. | Reac/Non-reac/Indet/Invalid / Reactive, Non-reactive, Indeterminate, Invalid | Reactive Non-Reactive Indeterminate Invalid Reactive (qualifer value) Non-Reactive (qualifer value) Indeterminate (qualifer value) |
LL1909-2 11214006 - SNOMEDCT 131194007 - SNOMEDCT 82334004 - SNOMEDCT |
Example | - |
| 4 | HIV 2 Ab [Presence] in Serum or Plasma by Immunoassay | Rapid/Screening HIV test | Y | 30361-0 | LOINC | - | Reactive w indet (3 answers, ord) / Whether an analyte is present or whether the result is indeterminate. | Indeterminate Reactive Non-Reactive Reactive (qualifer value) Non-Reactive (qualifer value) Indeterminate (qualifer value) |
LL2017-3 11214006 - SNOMEDCT 131194007 - SNOMEDCT 82334004 - SNOMEDCT |
Example | - |
| 5 | HIV 1+2 Ab [Presence] in Serum or Plasma by Immunoassay | Rapid/Screening HIV test | Y | 31201-7 | LOINC | - | - | Positive (qualifier value) Negative (qualifier value) |
10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- | - |
| 6 | HIV 1 RNA [Log #/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 1.7 log copies/mL | Supplemental/Confirmatory HIV test | Y | 48510-2 | LOINC | - | - | Not applicable Quantitative lab |
Not applicable | Not applicable | - |
| 7 | HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by Probe and target amplification method detection limit = 50 copies/mL | Supplemental/Confirmatory HIV test | Y | 48511-0 | LOINC | - | Not applicable Quantitative lab |
Not applicable | Not applicable | - | |
| End of worksheet |
Sheet 10: Syphilis Tests Panel
| Table 8. Syphilis Tests Panel | ||||||||||
| blank row | ||||||||||
| Data Element # | FPAR 2.0 Data Element (Long Common Name) |
In FPAR Panel? | Data Element Code (If Available) |
Standard Terminology Code System | Term Description | Value Set/Answer List Name | Response Descriptions | Expected Codes/Values | Binding to Answer List/Result Values | Notes |
| 1 | Reagin Ab [Titer] in Serum | N | 11084-1 | LOINC | - | - | Not applicable Quantitative lab (Titer) |
Not applicable | Not applicable | - |
| 2 | Reagin Ab [Presence] in Specimen by VDRL | N | 14904-7 | LOINC | - | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 3 | Reagin Ab [Presence] in Serum by RPR | N | 20507-0 | LOINC | - | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 4 | Reagin Ab [Units/volume] in Serum or Plasma by RPR | N | 20508-8 | LOINC | - | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | - | - |
| 5 | Reagin Ab [Presence] in Serum | N | 22461-8 | LOINC | - | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 6 | Reagin Ab [Units/volume] in Serum | N | 22462-6 | LOINC | - | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 7 | Reagin Ab [Presence] in Specimen | N | 22464-2 | LOINC | - | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 8 | Reagin Ab [Titer] in Serum by RPR | N | 31147-2 | LOINC | - | - | Not applicable Quantitative lab (Titer) |
Not applicable | Not applicable | - |
| 9 | Reagin Ab [Titer] in Specimen by VDRL | N | 47235-7 | LOINC | - | - | Not applicable Quantitative lab (Titer) |
Not applicable | Not applicable | - |
| 10 | Reagin Ab [Titer] in Specimen | N | 47476-7 | LOINC | - | - | Not applicable Quantitative lab (Titer) |
Not applicable | Not applicable | - |
| 11 | Reagin Ab [Titer] in Serum by VDRL | N | 50690-7 | LOINC | - | - | Not applicable Quantitative lab (Titer) |
Not applicable | Not applicable | - |
| 12 | Reagin Ab [Units/volume] in Serum by VDRL | N | 5291-0 | LOINC | - | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 13 | Reagin Ab [Presence] in Serum by VDRL | N | 5292-8 | LOINC | - | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 14 | Reagin and Treponema pallidum IgG and IgM [Interpretation] in Serum or Plasma | N | 73752-8 | LOINC | - | - | No serological evidence of current or past infection Biological false positive Early primary syphilis Treated syphilis Person from a country endemic for yaws, pinta or bejel May represent a biological false positive May be infectious syphilis if no previous history of syphilis Consistent with active infectious syphilis |
LL2467-0 | - | - |
| 15 | Treponema pallidum Ab [Units/volume] in Serum | N | 11597-2 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 16 | Treponema pallidum Ab [Units/volume] in Blood by Immunofluorescence | N | 13288-6 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 17 | Treponema pallidum Ab [Presence] in Serum by Immobilization | N | 17723-8 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 18 | Treponema pallidum Ab [Units/volume] in Serum by Immunofluorescence | N | 17724-6 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 19 | Treponema pallidum Ab [Units/volume] in Serum by Latex agglutination | N | 17725-3 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 20 | Treponema pallidum IgG Ab [Presence] in Serum by Immunofluorescence | N | 17726-1 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
- | - | - |
| 21 | Treponema pallidum IgG Ab [Units/volume] in Serum by Immunofluorescence | N | 17727-9 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 22 | Treponema pallidum IgM Ab [Units/volume] in Serum by Immunofluorescence | N | 17728-7 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 23 | Treponema pallidum IgM Ab [Presence] in Serum by Immunofluorescence | N | 17729-5 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 24 | Treponema pallidum Ab [Units/volume] in Blood | N | 22585-4 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 25 | Treponema pallidum Ab [Presence] in Serum | N | 22587-0 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 26 | Treponema pallidum Ab [Titer] in Serum | N | 22590-4 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab (Titer) |
Not applicable | Not applicable | - |
| 27 | Treponema pallidum IgG Ab [Units/volume] in Serum | N | 22592-0 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 28 | Treponema pallidum IgM Ab [Units/volume] in Serum | N | 22594-6 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 29 | Treponema pallidum Ab [Presence] in Serum by Immunoassay | N | 24110-9 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 30 | Treponema pallidum Ab [Presence] in Serum by Agglutination | N | 24312-1 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 31 | Treponema pallidum Ab [Titer] in Serum by Hemagglutination | N | 26009-1 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab |
Not applicable | Not applicable | - |
| 32 | Treponema pallidum [Presence] in Specimen by Immunofluorescence | N | 29310-0 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 33 | Treponema pallidum IgG+IgM Ab [Presence] in Serum | N | 34147-9 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifer value) Non-Reactive (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 34 | Treponema pallidum Ab [Titer] in Serum by Immunofluorescence | N | 34382-2 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab (Titer) |
Not applicable | Not applicable | - |
| 35 | Treponema pallidum Ab [Units/volume] in Body fluid by Hemagglutination | N | 39015-3 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 36 | Treponema pallidum IgG Ab [Presence] in Serum by Immunoblot | N | 40679-3 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 37 | Treponema pallidum IgM Ab [Presence] in Serum by Immunoblot | N | 40680-1 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 38 | Treponema pallidum Ab [Units/volume] in Specimen | N | 41122-3 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 39 | Treponema pallidum DNA [Presence] in Specimen by NAA with probe detection | N | 41163-7 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | 91134-7Sexually transmitted pathogens panel - Specimen by NAA with probe detection 96611-9Treponema pallidum and Haemophilus ducreyi and Herpes simplex virus DNA panel - Specimen by NAA with probe detection |
| 40 | Treponema pallidum IgG+IgM Ab [Presence] in Serum by Immunoassay | N | 47236-5 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 41 | Treponema pallidum IgM Ab [Presence] in Serum by Immunoassay | N | 47237-3 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 42 | Treponema pallidum IgG Ab [Presence] in Serum by Immunoassay | N | 47238-1 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 43 | Treponema pallidum Ab [Units/volume] in Body fluid | N | 47511-1 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 44 | Treponema pallidum IgG Ab [Units/volume] in Serum by Immunoassay | N | 51838-1 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 45 | Treponema pallidum IgM Ab [Units/volume] in Serum by Immunoassay | N | 51839-9 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 46 | Treponema pallidum DNA [Presence] in Blood by NAA with probe detection | N | 53605-2 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 47 | Treponema pallidum Ab [Units/volume] in Serum by Immobilization | N | 5392-6 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | Not applicable | - |
| 48 | Treponema pallidum Ab [Presence] in Serum by Immunofluorescence | N | 5393-4 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 49 | Treponema pallidum Ab [Titer] in Serum by Latex agglutination | N | 5394-2 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab (Titer) |
Not applicable | Not applicable | - |
| 50 | Treponema pallidum Ab [Presence] in Serum by Immunoblot | N | 57032-5 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 51 | Treponema pallidum Ab [Units/volume] in Serum by Immunoassay | N | 63464-2 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab ([arb'U]/mL) |
Not applicable | - | - |
| 52 | Treponema pallidum IgG Ab [Presence] in Serum | N | 6561-5 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 53 | Treponema pallidum IgM Ab [Presence] in Serum | N | 6562-3 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 54 | Treponema pallidum Ab [Titer] in Serum or Plasma by Agglutination | N | 71793-4 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Not applicable Quantitative lab (Titer) |
Not applicable | - | - |
| 55 | Treponema pallidum polA gene [Presence] in Genital specimen by NAA with probe detection | N | 76766-5 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Positive (qualifier value) Negative (qualifier value) |
LL360-9 10828004 - SNOMEDCT 260385009 - SNOMEDCT |
- | - |
| 56 | Treponema pallidum Ab [Presence] in Serum by Hemagglutination | N | 8041-6 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Reactive (qualifier value) Non-reactive (qualifier value) Positive (qualifier value) Detected (qualifer value) Negative (qualifier value) Not detected (qualifer value) Equivocal (qualifer value) Indeterminate (qualifer value) |
11214006 - SNOMEDCT 131194007 – SNOMEDCT 10828004 - SNOMEDCT 260373001 - SNOMEDCT 260385009 - SNOMEDCT 260415000 - SNOMEDCT 42425007 - SNOMEDCT 82334004 - SNOMEDCT |
- | - |
| 57 | Treponema pallidum DNA [Presence] in Genital specimen by NAA with probe detection | N | 91846-6 | LOINC | Treponema pallidum is a spirochaete bacterium. Pathogenic treponemes are classified based upon their clinical manifestations in humans: venereal syphilis, yaws, endemic syphilis and pinta. Nonpathogenic treponemes are often part of the normal flora of the genital tract, oral cavity or intestinal tract. Treponemal infections exhibit diverse clinical manifestations which are characterized by distinct clinical stages. Multiplication of the bacterium at the entry point causes the primary stage. Dissemination of treponemes to other tissues produces the second stage. After a latency period (up to 20 to 30 years), the tertiary stage develops. T. palladum subsp pallidum (venereal syphilis) is the most destructive subspecies and produces lesions in many bodily tissues including the central nervous system. Congenital syphilis may result in birth defects or fetal death. Venereal syphilis is sexually acquired except for congenital syphilis, which is transmitted to the fetus during the later stages of pregnancy. The other treponemes are acquired by close nonvenereal contact. Control of both venereal and nonvenereal disease is based upon surveillance and antibiotic treatment of contacts. [NCBI Books:NBK7716] | - | Detected Not detected |
260373001 - SNOMEDCT 260415000 - SNOMEDCT |
- | - |
| End of worksheet |
| File Type | application/vnd.openxmlformats-officedocument.spreadsheetml.sheet |
| File Modified | 0000-00-00 |
| File Created | 0000-00-00 |
© 2024 OMB.report | Privacy Policy